Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers

Health Canada Approves ELAHERE® for Certain Types of Platinum-Resistant Ovarian Cancers

  • Health Canada has approved ELAHERE ® , the first novel therapy to demonstrate statistically significant and clinically meaningful improvements in overall survival (OS) compared to chemotherapy alone for patients with platinum-resistant ovarian cancer (PROC). 1
  • ELAHERE ® received approval through Health Canada's Priority Review process, based on data from the pivotal MIRASOL Phase 3 trial, establishing it as a potential new standard of care for folate receptor alpha (FRα)-positive PROC). 1
  • ELAHERE ® is the first and only Health Canada approved antibody-drug conjugate (ADC) targeting FRα, offering a new treatment option for a disease with the lowest survival rate among gynecological cancers in Canada .

Today, AbbVie (NYSE: ABBV) has announced that under the Priority Review process, Health Canada has approved ELAHERE ® (mirvetuximab soravtansine for injection), an antibody-drug conjugate (ADC), for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. 1

"Ovarian cancer poses many unique challenges for women. In addition to vague symptoms and late-stage diagnosis, many patients develop a resistance to current treatments that increases their risk of poor survival outcomes," said Tania Vrionis , CEO of Ovarian Cancer Canada, the only national health charity focused on supporting women facing ovarian cancer. "The approval of ELAHERE ® in Canada is not only welcome news for women in our community, but also a critically needed update to their care. This decision gives them another treatment option and can help improve outcomes for those who are no longer responding to surgery and chemotherapy."

"Platinum-resistant ovarian cancer is a challenging disease with limited effective therapies and a poor prognosis," said Dr. Shannon Salvador , President of the Society of Gynecologic Oncologists of Canada , Associate Professor at McGill University , and Director of the Gynecologic Oncology Subspecialty Residency Program. "This approval marks a critical advancement in the treatment of advanced ovarian cancer. ELAHERE ® has been shown to extend the survival of patients and offers a much-needed new option for those facing this form of gynecological cancer, which has the lowest survival rate in Canada ."

"This new treatment is the first in over a decade for this type of ovarian cancer and marks a major milestone for patients," said Rami Fayed, Vice President and General Manager of AbbVie Canada. "We take seriously our responsibility to research, develop and introduce therapies that impact patients' lives and AbbVie is committed to developing treatments for hard-to-treat cancers to help improve patients' outcomes and quality of life."

About The Phase 3 MIRASOL Trial
MIRASOL is a randomized Phase 3 trial evaluating the efficacy and safety of ELAHERE ® (mirvetuximab soravtansine for injection) versus investigator's choice (IC) of single-agent chemotherapy. Eligibility criteria included patients with PROC whose tumors express high levels of FRα, as determined using the Ventana FOLR1 RxDx Assay, and who have been treated with one to three prior systemic regimens. The trial enrolled 453 patients. The primary endpoint was progression-free survival (PFS) by investigator assessment, and key secondary endpoints included objective response rate (ORR) and overall survival (OS).

The OS hazard ratio (HR) was 0.67 (95% confidence interval [CI]: 0.50, 0.88; p=0.0046), representing a 33% statistically significant and clinically meaningful reduction in risk of death in the ELAHERE ® arm compared to the IC chemotherapy arm. The PFS HR was 0.65 (95% CI: 0.52, 0.81; p ® arm compared to IC chemotherapy. ORR in the ELAHERE ® arm was 42% (95% CI: 35.8%–49.0%) compared to 16% (95% CI: 11.4%–21.4%) in the IC chemotherapy arm. Additionally, 5% of patients in the ELAHERE ® arm achieved a complete response, versus 0% in the chemotherapy arm.

In this trial, serious adverse reactions occurred in 24% of patients treated with ELAHERE ® . The most common (≥ 2%) serious adverse events were pleural effusion (3%), abdominal pain (3%), intestinal obstruction (2%), ascites (2%) and small intestinal obstruction (2%).

About Ovarian Cancer
Ovarian cancer is the leading cause of death from gynecological cancers in Canada . 2 Each year, an estimated 3,000 women are diagnosed. 3 Most patients present with late-stage disease and will typically undergo surgery followed by platinum-based chemotherapy. 4 Unfortunately, the majority of patients eventually develop platinum-resistant disease, which is difficult to treat. 4 In this setting, standard of care chemotherapies with or without bevacizumab are associated with low response rates, poor prognosis, short durations of response, and significant toxicities. 5

About ELAHERE ®
ELAHERE ® (mirvetuximab soravtansine for injection) is the first and only FRα-targeted ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. Please consult the ELAHERE ® Product Monograph at https://www.abbvie.ca/en/our-science/products.html .

About AbbVie in Oncology
At AbbVie, we are committed to transforming standards of care for multiple cancers while advancing a dynamic pipeline of investigational therapies across a range of cancer types. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potentially breakthrough medicines. We are evaluating more than 35 investigational medicines in over 300 clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, gynecology and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.ca . Follow AbbVie Canada on Instagram , or LinkedIn .

References

_____________________

1 ELAHERE (mirvetuximab soravtansine for injection) product monograph. AbbVie Corporation. Available at: https://www.abbvie.ca/content/dam/abbvie-dotcom/ca/en/documents/products/ELAHERE_PM_EN.pdf

2 Statistics Canada. Trends in the incidence and mortality of female reproductive system cancers. 2015. Available at: https://www150.statcan.gc.ca/n1/pub/82-624-x/2015001/article/14212-eng.htm

3 Canadian Cancer Society. Ovarian cancer statistics. 2024. Available at: https://cancer.ca/en/cancer-information/cancer-types/ovarian/statistics

4 Wang, L., Wang, X., Zhu, X. et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer 23, 66 (2024). https://doi.org/10.1186/s12943-024-01967-3

5 Gonzalez-Ochoa E, Veneziani AC, Oza AM. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer. Clin Med Insights Oncol. 2023 Jul 25;17:11795549231187264. doi: 10.1177/11795549231187264. PMID: 37528890; PMCID: PMC10387675.

SOURCE AbbVie Canada

News Provided by PR Newswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1
- RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in Canada 1, 2, 3

AbbVie (NYSE: ABBV), today announced that Health Canada has approved RINVOQ ® (upadacitinib, 15 mg), the first oral, once-daily selective and reversible JAK inhibitor for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have had an inadequate response to a biologic disease modifying anti-rheumatic drug (DMARD) or when use of those therapies is inadvisable.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6 to 17 years

- Twenty-nine abstracts showcase AbbVie's vast portfolio and continued commitment to changing the way patients living with gastrointestinal disorders manage their condition

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona's patents for TFC-1067 and related family of compounds.

"We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica™, a leader in the science of skin rejuvenation," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing. We would like to thank Dr. Linda Pullan of Pullan Consulting who assisted with our current success."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2025

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With global spending on medicine using list prices growing by 38 percent over the past five years and a forecasted increase of 35 percent through 2029, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics


Keep reading...Show less
Seegnal Inc. (TSXV:SEGN)

Seegnal Inc. Announces Extension of Maccabi Health Services Contract

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, is pleased to announce that effective September 8, 2025, it has amended its contract with Maccabi Health Services ("Maccabi") for an additional six years and has also expanded the scope of the contract to include all of Maccabi's pharmacies and additional nurses. Maccabi is the second largest Healthcare Management Organization ("HMO") in Israel, serving over 2.6 million Israelis and is renowned for its use of technology and emphasis on patient-centered care, according to Maccabi's website here.

Pursuant to the amended agreement, Seegnal will continue to deliver its patented prescription co-pilot platform for an additional six years, to September 22, 2031, while expanding the scope to nurses and pharmacists in all of Maccabi's nationwide pharmacies. Maccabi is the first in Israel and one of the first HMOs worldwide to offer an end-to-end safety coverage throughout the patient journey, allowing complete visibility to pharmacists in the pharmacies into clinician decision while prescribing patient centric medication. The expanded contract was changed from a fixed base contract to Seegnal's current SaaS based model based on Quarterly Recurring License Fees and is expected to generate additional revenue for the Corporation.

Keep reading...Show less
Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Third Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company") a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended May 31, 2025 ("Q3 2025 ").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Invion Executive Chair and CEO Thian Chew.

Invion CEO Maps Path to Peer-level Valuation as Momentum for Cancer Treatment Trials Builds

Invion (ASX:IVX) Executive Chair and CEO Thian Chew says the company sees a path to a rerate toward clinical-stage oncology peers — typically valued from AU$30 million to AU$40 million up to several hundred million — if it executes on a trio of near-term priorities: simplifying licencing, cleaning up shareholder financing structures and dialling up investor awareness.

In an interview with the Investing News Network, Chew stressed that Invion’s fundamentals are already in place: a platform therapy being tested across multiple cancers with an active clinical program, and a US Food and Drug Administration orphan drug designation potentially fast tracking approvals.

“The challenge is making sure people invest the time to understand where we're at. So if we solve all those three, even without doing any more development work, then we believe that we can get around the comparable levels of valuation, and that creates some interesting opportunities for us,” Chew said.

Keep reading...Show less
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results

All financial results are reported in Canadian dollars unless otherwise stated.

Numinus Wellness Inc.  (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025").

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News